Mucins in ovarian cancer diagnosis and therapy

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Chauhan, Subhash C ^a,b   Kumar, Deepak ^c   Jaggi, Meena ^a,b  

^a SANFORD RESEARCH   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c UNIVERSITY OF THE DISTRICT OF COLUMBIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CANCER VACCINE; CD146 ANTIGEN; COPPER 67; DENDRITIC CELL VACCINE; GLYCOPROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDIUM 111; MONOCLONAL ANTIBODY; MUC11; MUC12; MUC13; MUC16; MUC17; MUC20; MUCIN; MUCIN 1; MUCIN 2; MUCIN 5AC; MUCIN 5B; MUCIN 6; MUCIN 7; MUCIN 8; OREGOVOMAB; RADIOISOTOPE; RHENIUM 188; TECHNETIUM 99M; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ASCITES TUMOR; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RISK; CANCER STAGING; CANCER THERAPY; CONTROLLED STUDY; EARLY DIAGNOSIS; EPITHELIUM; GAMMA RADIATION; GENE LOCUS; GENETIC ENGINEERING; GERM CELL TUMOR; GOBLET CELL; IMMUNE RESPONSE; IMMUNOGENICITY; ISOTOPE LABELING; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OVARY CANCER; PATHOGENESIS; PERITONEUM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SURVIVAL RATE; TUMOR CLASSIFICATION;

EID: 77953441241     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-21     Document Type: Review

References (97)

1. Ovarian cancer screening. F Alexander-Sefre U Menon IJ Jacobs, Hosp Med 2002 63 210 213 11995270
2. Update on the management of ovarian cancer. RF Ozols, Cancer J 2002 8 Suppl 1 22 30 12075699
3. The biology of ovarian cancer. N Auersperg MI Edelson SC Mok SW Johnson TC Hamilton, Semin Oncol 1998 25 281 304 9633841
4. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. N Auersperg T Ota GW Mitchell, Int J Gynecol Cancer 2002 12 691 703 10.1046/j.1525-1438.2002.01152.x 12445245
5. Ovarian surface epithelium: biology, endocrinology, and pathology. N Auersperg AS Wong KC Choi SK Kang PC Leung, Endocr Rev 2001 22 255 288 10.1210/er.22.2.255 11294827
6. Epidemiology and risk assessment for ovarian cancer. M Daly GI Obrams, Semin Oncol 1998 25 255 264 9633839
7. A prospective study of reproductive factors and risk of epithelial ovarian cancer. SE Hankinson GA Colditz DJ Hunter WC Willett MJ Stampfer B Rosner CH Hennekens FE Speizer, Cancer 1995 76 284 290 10.1002/1097- 0142(19950715)76:2<284::AID-CNCR28207602193.0.CO;2-5 8625104
8. Estrogen replacement therapy following oophorectomy in women with a family history of ovarian cancer. GH Eltabbakh MS Piver RE Hempling FO Recio C Aiduk, Gynecol Oncol 1997 66 103 107 10.1006/gyno.1997.4723 9234929
9. Hormone replacement therapy as a risk factor for epithelial ovarian cancer: results of a case-control study. RE Hempling C Wong MS Piver N Natarajan CJ Mettlin, Obstet Gynecol 1997 89 1012 1016 10.1016/S0029-7844(97)00118-X 9170483
10. Ovarian tumors in a cohort of infertile women. MA Rossing JR Daling NS Weiss DE Moore SG Self, N Engl J Med 1994 331 771 776 10.1056/ NEJM199409223311204 8065405
11. Genetics and ovarian carcinoma. HT Lynch MJ Casey J Lynch TE White AK Godwin, Semin Oncol 1998 25 265 280 9633840
12. Hereditary Factors in Gynecologic Cancer. HT Lynch MJ Casey TG Shaw JF Lynch, Oncologist 1998 3 319 338 10388122
13. Hereditary gynecologic cancer. HT Lynch S Lemon J Lynch MJ Casey, Cancer Treat Res 1998 95 1 102 9619280
14. Ovarian cancer screening. SE Mackey WT Creasman, J Clin Oncol 1995 13 783 793 7884436
15. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. DB Berman J Wagner-Costalas DC Schultz HT Lynch M Daly AK Godwin, Am J Hum Genet 1996 58 1166 1176 8651293
16. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. DC Schultz L Vanderveer DB Berman TC Hamilton AJ Wong AK Godwin, Cancer Res 1996 56 1997 2002 8616839
17. Biomarkers in the ovary. A Berchuck, J Cell Biochem Suppl 1995 23 223 226 10.1002/jcb.240590930 8747400
18. Molecular aspects of ovarian cancer. RM Wenham JM Lancaster A Berchuck, Best Pract Res Clin Obstet Gynaecol 2002 16 483 497 10.1053/beog.2002.0298 12413930
19. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer. RM Wenham JM Schildkraut K McLean B Calingaert RC Bentley J Marks A Berchuck, Clin Cancer Res 2003 9 4396 4403 14555511
20. Ovarian surface epithelium: family history and early events in ovarian cancer. AS Wong N Auersperg, Reprod Biol Endocrinol 2003 1 70 10.1186/1477-7827-1-70 14609432
21. Prognostic factors in ovarian cancer. ML Friedlander, Semin Oncol 1998 25 305 314 9633842
22. Epithelial mucin genes. SJ Gendler AP Spicer, Annu Rev Physiol 1995 57 607 634 10.1146/annurev.ph.57.030195.003135 7778880
23. Mucin genes and the proteins they encode: structure, diversity, and regulation. JR Gum Jr, Am J Respir Cell Mol Biol 1992 7 557 564 1449803
24. Mucins in cancer: protection and control of the cell surface. MA Hollingsworth BJ Swanson, Nat Rev Cancer 2004 4 45 60 10.1038/nrc1251 14681689
25. Intestinal mucins in health and disease. JF Forstner, Digestion 1978 17 234 263 10.1159/000198115 25218
26. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. SJ Gendler CA Lancaster J Taylor-Papadimitriou T Duhig N Peat J Burchell L Pemberton EN Lalani D Wilson, J Biol Chem 1990 265 15286 15293 1697589
27. Subunit structure of porcine submaxillary mucin. R Gupta N Jentoft, Biochemistry 1989 28 6114 6121 10.1021/bi00440a058 2775758
28. Porcine submaxillary gland apomucin contains tandemly repeated, identical sequences of 81 residues. CS Timpte AE Eckhardt JL Abernethy RL Hill, J Biol Chem 1988 263 1081 1088 2826455
29. Structural organization and classification of the human mucin genes. N Moniaux F Escande N Porchet JP Aubert SK Batra, Front Biosci 2001 6 1192 1206 10.2741/Moniaux 11578969
30. Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. JR Gum Jr JW Hicks NW Toribara B Siddiki YS Kim, J Biol Chem 1994 269 2440 2446 8300571
31. Human mucin gene MUC5AC: organization of its 5'-region and central repetitive region. F Escande JP Aubert N Porchet MP Buisine, Biochem J 2001 358 763 772 10.1042/0264-6021:3580763 11535137
32. Genomic organization of the human mucin gene MUC5B. cDNA and genomic sequences upstream of the large central exon. JL Desseyn MP Buisine N Porchet JP Aubert A Laine, J Biol Chem 1998 273 30157 30164 10.1074/jbc.273.46.30157 9804771
33. The carboxyl-terminal sequence of the human secretory mucin, MUC6. Analysis Of the primary amino acid sequence. NW Toribara SB Ho E Gum JR Gum Jr P Lau YS Kim, J Biol Chem 1997 272 16398 16403 10.1074/jbc.272.26.16398 9195947
34. Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). LA Bobek H Tsai AR Biesbrock MJ Levine, J Biol Chem 1993 268 20563 20569 7690757
35. Upregulation of MUC8 and downregulation of MUC5AC by inflammatory mediators in human nasal polyps and cultured nasal epithelium. JK Seong JS Koo WJ Lee HN Kim JY Park KS Song JH Hong JH Yoon, Acta Otolaryngol 2002 122 401 407 10.1080/00016480260000094 12125997
36. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. SJ Williams MA McGuckin DC Gotley HJ Eyre GR Sutherland TM Antalis, Cancer Res 1999 59 4083 4089 10463611
37. Multiple transcripts of MUC3: evidence for two genes, MUC3A and MUC3B. WS Pratt S Crawley J Hicks J Ho M Nash YS Kim JR Gum DM Swallow, Biochem Biophys Res Commun 2000 275 916 923 10.1006/bbrc.2000.3406 10973822
38. Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin. N Moniaux S Nollet N Porchet P Degand A Laine JP Aubert, Biochem J 1999 338 Pt 2 325 333 10.1042/0264-6021:3380325 10024507
39. Allelic polymorphism and chromosomal localization of the human oviductin gene (MUC9). L Lapensee Y Paquette G Bleau, Fertil Steril 1997 68 702 708 10.1016/S0015-0282(97)00317-8 9341614
40. An alternatively spliced Muc10 glycoprotein ligand for putative L-selectin binding during mouse embryonic submandibular gland morphogenesis. M Melnick H Chen Y Zhou T Jaskoll, Arch Oral Biol 2001 46 745 757 10.1016/S0003-9969(01)00027-9 11389866
41. Muc13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. SJ Williams DH Wreschner M Tran HJ Eyre GR Sutherland MA McGuckin, J Biol Chem 2001 276 18327 18336 10.1074/jbc.M008850200 11278439
42. Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. BW Yin A Dnistrian KO Lloyd, Int J Cancer 2002 98 737 740 10.1002/ijc.10250 11920644
43. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. BW Yin KO Lloyd, J Biol Chem 2001 276 27371 27375 10.1074/jbc.M103554200 11369781
44. MUC17, a novel membrane-tethered mucin. JR Gum Jr SC Crawley JW Hicks DE Szymkowski YS Kim, Biochem Biophys Res Commun 2002 291 466 475 10.1006/bbrc.2002.6475 11855812
45. Fully human antibodies to MCAM/MUC18 inhibit tumor growth and metastasis of human melanoma. L Mills C Tellez S Huang C Baker M McCarty L Green JM Gudas X Feng M Bar-Eli, Cancer Res 2002 62 5106 5114 12208768
46. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. T Higuchi T Orita S Nakanishi K Katsuya H Watanabe Y Yamasaki I Waga T Nanayama Y Yamamoto W Munger H Sun R Falk J Jennette D Alcorta H Li T Yamamoto Y Saito M Nakamura, J Biol Chem 2004 279 1968 1979 10.1074/jbc.M304558200 14565953
47. Mucin gene expression in ovarian cancers. RL Giuntoli GC Rodriguez RS Whitaker R Dodge JA Voynow, Cancer Res 1998 58 5546 5550 9850092
48. Mucin gene transcripts in benign and borderline mucinous tumours of the ovary: an in situ hybridization study. F Boman MP Buisine A Wacrenier D Querleu JP Aubert N Porchet, J Pathol 2001 193 339 344 10.1002/1096-9896(2000)9999: 9999<::AID-PATH7983.0.CO;2-9 11241413
49. Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. Y Dong MD Walsh MC Cummings RG Wright SK Khoo PG Parsons MA McGuckin, J Pathol 1997 183 311 317 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH9173.0.CO;2-2 9422987
50. Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. H Feng M Ghazizadeh H Konishi T Araki, Jpn J Clin Oncol 2002 32 525 529 10.1093/jjco/hyf111 12578901
51. Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. C Hanski M Hofmeier A Schmitt-Graff E Riede ML Hanski F Borchard E Sieber F Niedobitek HD Foss H Stein EO Riecken, J Pathol 1997 182 385 391 10.1002/(SICI)1096- 9896(199708)182:4<385::AID-PATH8613.0.CO;2-Q 9306958
52. Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). SC Chauhan AP Singh F Ruiz SL Johansson M Jain LM Smith N Moniaux SK Batra, Mod Pathol 2006 19 1386 1394 10.1038/modpathol.3800646 16880776
53. Expression and functions of transmembrane mucin MUC13 in ovarian cancer. SC Chauhan K Vannatta MC Ebeling N Vinayek A Watanabe KK Pandey MC Bell MD Koch H Aburatani Y Lio M Jaggi, Cancer Res 2009 69 765 774 10.1158/0008-5472.CAN-08- 0587 19176398
54. Decreased MUC1 expression induces E-cadherin-mediated cell adhesion of breast cancer cell lines. K Kondo N Kohno A Yokoyama K Hiwada, Cancer Res 1998 58 2014 2019 9581847
55. A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. J Wesseling SW van der Valk J Hilkens, Mol Biol Cell 1996 7 565 577 8730100
56. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Wesseling SW van der Valk HL Vos A Sonnenberg J Hilkens, J Cell Biol 1995 129 255 265 10.1083/jcb.129.1.255 7698991
57. Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. KG Kohlgraf AJ Gawron M Higashi JL Meza MD Burdick S Kitajima DL Kelly TC Caffrey MA Hollingsworth, Cancer Res 2003 63 5011 5020 12941828
58. Reversible disruption of cell-matrix and cell-cell interactions by overexpression of sialomucin complex. M Komatsu CA Carraway NL Fregien KL Carraway, J Biol Chem 1997 272 33245 33254 10.1074/jbc.272.52.33245 9407114
59. Potentiation of metastasis by cell surface sialomucin complex (rat MUC4), a multifunctional anti-adhesive glycoprotein. M Komatsu L Tatum NH Altman CA Carothers Carraway KL Carraway, Int J Cancer 2000 87 480 486 10.1002/1097-0215(20000815)87:4<480::AID-IJC43.0.CO;2-6 10918186
60. Overexpression of sialomucin complex, a rat homologue of MUC4, inhibits tumor killing by lymphokine-activated killer cells. M Komatsu L Yee KL Carraway, Cancer Res 1999 59 2229 2236 10232613
61. MUC1 and MUC2 expression in human gallbladder carcinoma: a clinicopathological study and relationship with prognosis. H Kashiwagi H Kijima S Dowaki Y Ohtani K Tobita H Yamazaki M Nakamura Y Ueyama M Tanaka S Inokuchi H Makuuchi, Oncol Rep 2001 8 485 489 11295067
62. The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Y Li D Kufe, Biochem Biophys Res Commun 2001 281 440 443 10.1006/bbrc.2001.4383 11181067
63. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-associated antigen with GSK3 beta and beta-catenin. Y Li H Kuwahara J Ren G Wen D Kufe, J Biol Chem 2001 276 6061 6064 10.1074/jbc.C000754200 11152665
64. The epidermal growth factor receptor regulates interaction of the human DF3/MUC1 carcinoma antigen with c-Src and beta-catenin. Y Li J Ren W Yu Q Li H Kuwahara L Yin KL Carraway D Kufe, J Biol Chem 2001 276 35239 35242 10.1074/jbc.C100359200 11483589
65. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. A Rump Y Morikawa M Tanaka S Minami N Umesaki M Takeuchi A Miyajima, J Biol Chem 2004 279 9190 9198 10.1074/jbc.M312372200 14676194
66. Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. JA Gubbels J Belisle M Onda C Rancourt M Migneault M Ho TK Bera J Connor BK Sathyanarayana B Lee I Pastan M Patankar, Mol Cancer 2006 5 50 10.1186/1476-4598-5-50 17067392
67. Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125). JA Belisle JA Gubbels CA Raphael M Migneault C Rancourt JP Connor MS Patankar, Immunology 2007 122 418 429 10.1111/j.1365-2567.2007.02660.x 17617155
68. Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? MG Wahrenbrock A Varki, Cancer Res 2006 66 2433 2441 10.1158/0008-5472.CAN-05-3851 16489050
69. CA 125: the past and the future. RC Bast Jr FJ Xu YH Yu S Barnhill Z Zhang GB Mills, Int J Biol Markers 1998 13 179 187 10228898
70. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. RC Bast Jr TL Klug E St John E Jenison JM Niloff H Lazarus RS Berkowitz T Leavitt CT Griffiths L Parker V Zurawski Jr R Knapp, N Engl J Med 1983 309 883 887 6310399
71. New tumor markers: CA125 and beyond. RC Bast Jr D Badgwell Z Lu R Marquez D Rosen J Liu KA Baggerly EN Atkinson S Skates Z Zhang A Lokshin U Menon I Jacobs Kl Lu, Int J Gynecol Cancer 2005 15 Suppl 3 274 281 10.1111/j.1525-1438. 2005.00441.x 16343244
72. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. GJ Rustin RC Bast Jr GJ Kelloff JC Barrett SK Carter PD Nisen CC Sigman DR Parkinson RW Ruddon, Clin Cancer Res 2004 10 3919 3926 10.1158/1078-0432.CCR-03-0787 15173101
73. Mucin glycoproteins in neoplasia. YS Kim J Gum Jr I Brockhausen, Glycoconj J 1996 13 693 707 10.1007/BF00702333 8909996
74. Mucin gene and antigen expression in biliopancreatic carcinogenesis. YS Kim JR Gum Jr SC Crawley G Deng JJ Ho, Ann Oncol 1999 10 Suppl 4 51 55 10.1023/A:1008332602541 10436785
75. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. JF Robertson W Jaeger JJ Syzmendera C Selby R Coleman A Howell J Winstanley PE Jonssen E Bombardieri JR Sainsbury H Gronberg E Kumpulainen RW Blamey, Eur J Cancer 1999 35 47 53 10.1016/S0959-8049(98)00297-4 10211087
76. CA 125 in ovarian cancer: advances and controversy. HA Fritsche RC Bast, Clin Chem 1998 44 1379 1380 9665412
77. The CA 125 tumour-associated antigen: a review of the literature. I Jacobs RC Bast Jr, Hum Reprod 1989 4 1 12 2651469
78. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. IJ Jacobs DH Oram RC Bast Jr, Obstet Gynecol 1992 80 396 399 1495694
79. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. IJ Jacobs H Rivera DH Oram RC Bast Jr, Br J Obstet Gynaecol 1993 100 1120 1124 8297846
80. MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. B Davidson M Baekelandt M Shih Ie, Diagn Cytopathol 2007 35 756 760 10.1002/dc.20771 18008338
81. Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. DW Cramer L Titus-Ernstoff JR McKolanis WR Welch AF Vitonis RS Berkowitz OJ Finn, Cancer Epidemiol Biomarkers Prev 2005 14 1125 1131 10.1158/1055-9965.EPI-05-0035 15894662
82. Imaging for staging bladder cancer: a clinical study of intravenous 111indium-labelled anti-MUC1 mucin monoclonal antibody C595. OD Hughes AC Perkins M Frier ML Wastie G Denton MR Price H Denley MC Bishop, BJU Int 2001 87 39 46 10.1046/j.1464-410x.2001.00985.x 11121991
83. Preclinical evaluation of copper-67 labelled anti-MUC1 mucin antibody C595 for therapeutic use in bladder cancer. OD Hughes MC Bishop AC Perkins M Frier MR Price G Denton A Smith R Rutherford PA Schubiger, Eur J Nucl Med 1997 24 439 443 9096097
84. Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595. OD Hughes MC Bishop AC Perkins ML Wastie G Denton MR Price M Frier H Denley R Rutherford PA Schubiger, J Clin Oncol 2000 18 363 370 10637251
85. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer. S McQuarrie J Mercer A Syme M Suresh G Miller, J Pharm Pharm Sci 2005 7 29 34 15850546
86. Nanomedicines for active targeting: Physico-chemical characterization of paclitaxel-loaded anti-HER2 immunonanoparticles and in vitro functional studies on target cells. A Cirstoiu-Hapca F Buchegger L Bossy M Kosinski R Gurny F Delie, Eur J Pharm Sci 2009 38 3 230 7 10.1016/j.ejps.2009.07.006 19632322
87. Pharmacokinetics and biodistribution of genetically engineered antibodies. SK Batra M Jain UA Wittel SC Chauhan D Colcher, Curr Opin Biotechnol 2002 13 603 608 10.1016/S0958-1669(02)00352-X 12482521
88. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. RA Graham JM Burchell J Taylor-Papadimitriou, Cancer Immunol Immunother 1996 42 71 80 10.1007/s002620050254 8620523
89. Mucins as immunogenic targets in cancer. KN Syrigos AJ Karayiannakis A Zbar, Anticancer Res 1999 19 5239 5244 10697542
90. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. P Brossart KS Heinrich G Stuhler L Behnke VL Reichardt S Stevanovic A Muhm HG Rammensee L Kanz W Brugger, Blood 1999 93 4309 4317 10361129
91. A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. JS Goydos E Elder TL Whiteside OJ Finn MT Lotze, J Surg Res 1996 63 298 304 10.1006/jsre.1996.0264 8667619
92. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. MA Reddish GD MacLean S Poppema A Berg BM Longenecker, Cancer Immunol Immunother 1996 42 303 309 10.1007/s002620050287 8706053
93. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. RA Graham JM Burchell P Beverley J Taylor-Papadimitriou, Int J Cancer 1996 65 664 670 10.1002/(SICI)1097-0215(19960301)65:5<664::AID-IJC173.0.CO;2-7 8598319
94. Long-term tumor growth suppression in mice immunized with naked DNA of the human tumor antigen mucin (MUC1). H Johnen H Kulbe G Pecher, Cancer Immunol Immunother 2001 50 356 360 10.1007/s002620100212 11676395
95. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. AJ Lepisto AJ Moser H Zeh K Lee D Bartlett JR McKolanis BA Geller A Schmotzer DP Potter T Whiteside OJ Finn RK Ramanathan, Cancer Ther 2008 6 955 964 19129927
96. Dendritic cell-based cancer immunotherapy targeting MUC-1. J Wierecky M Mueller P Brossart, Cancer Immunol Immunother 2006 55 63 67 10.1007/s00262-005- 0673-6 15864588
97. A distinct molecular profile associated with mucinous epithelial ovarian cancer. VA Heinzelmann-Schwarz M Gardiner-Garden SM Henshall JP Scurry RA Scolyer AN Smith A Bali P Vanden Bergh S Baron-Hay C Scott D Fink NF Hacker RL Sutherland PM O'Brien, Br J Cancer 2006 94 904 913 10.1038/sj.bjc.6603003 16508639